Who
Gaurav Shah
CEO
Company insider
Files Form 4 as: CEO, Rocket Pharmaceuticals; Director, Talaris Therapeutics.
In numbers
- Trades disclosed
- 99
- Buys
- 2
- Sells
- 21
- Bought
- $483K
- Sold
- $3.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 Mar 2018
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,7532,293 at $3.38 | filing |
| 18 Aug 2026filed 20 Aug 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,7502,293 at $3.38 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,5922,837 at $3.38 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,5892,837 at $3.38 | filing |
| 21 May 2026filed 26 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $129K76,490 at $1.69 | filing |
| 21 May 2026filed 26 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $172K55,684 at $3.09 | filing |
| 21 May 2026filed 26 May 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $129K76,490 at $1.69 | filing |
| 21 May 2026filed 26 May 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $129K76,490 at $1.69 | filing |
| 21 May 2026filed 26 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $129K76,490 at $1.69 | filing |
| 21 May 2026filed 26 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $172K55,684 at $3.09 | filing |
| 19 May 2026filed 21 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,2612,409 at $3.01 | filing |
| 19 May 2026filed 21 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,2512,409 at $3.01 | filing |
| 13 May 2026filed 14 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,8372,728 at $3.61 | filing |
| 13 May 2026filed 14 May 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $9,8482,728 at $3.61 | filing |
| 18 Feb 2026filed 20 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $20K5,990 at $3.34 | filing |
| 18 Feb 2026filed 20 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $20K5,990 at $3.34 | filing |
| 13 Feb 2026filed 18 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K12,279 at $3.31 | filing |
| 13 Feb 2026filed 18 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K12,279 at $3.31 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RCKT Rocket PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —286,028 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RCKT Rocket Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —870,648 at $0.00 | filing |
News
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Crosses Below Fifty Day Moving Average – Should You Sell?RCKT · dailypolitical.com · 22 Oct 2026
0 headlines in the last 90 days name Gaurav Shah; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.